Personalized heparin calculator aims to speed up clot treatment
NCT ID NCT07250763
First seen Jan 09, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tests whether using a patient's gender, weight, and kidney function to calculate the starting dose of the blood thinner heparin gets patients to the right level faster than the standard flat rate. About 145 adults with blood clots, atrial fibrillation, or mechanical heart valves will receive a personalized starting dose. The goal is to see if this approach reduces time to effective treatment and lowers the risk of over- or under-dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Inova Alexandria Hospital
Alexandria, Virginia, 22304, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
unfractionated heparin (blood thinner)
What this could lead to
If successful, this could make heparin treatment safer and more effective by reaching the right dose faster, reducing complications from clots or bleeding.
What could go wrong
This is a small, single-center study comparing against historical data, not a randomized trial. The personalized calculator may not work better in all patients or settings.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.